Brian Boyd
Pain Medicine · Orange, CANPI 1932242302
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,003 of the $127,015 with a category attached, or 86.6%. AbbVie accounts for 87.9% of it on its own, with 44 other manufacturers making up the rest. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $201.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$112K
- Pfizer$7K
- Amgen$1K
- Supernus Pharmaceuticals, Inc.$881
- Upsher-smith Laboratories LLC$877
- Teva Pharmaceuticals USA, Inc.$814
- plus $5K from 39 others
What the payments were for
- Consulting fees$3,3253%
- Speaking & faculty fees$110,00387%
- Travel & lodging$150%
- Food & beverage$13,66011%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$86,274
- QULIPTA$50,207
- NURTEC ODT$6,820
- AIMOVIG$494
- Austedo XR$238
- BOTOX$233
- AJOVY$227
- SONOPET IQ$149
- NA$149
- ELYXYB - CELECOXIB$141
- OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex)$140
- TECENTRIQ$130
- VYEPTI$125
- ZAVZPRET$125
- Leqembi$120
- Orilissa$117
- AVANCE NERVE GRAFT$115
- ZEJULA$105
How this compares
$127,015 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 36 | $43,210 |
| UbrelvyUbrogepant | 27 | $39,990 |
| BotoxOnabotulinumtoxina | 20 | $25,498 |
| Emgality PenGalcanezumab-Gnlm | 20 | $16,256 |
| Nurtec OdtRimegepant Sulfate | 12 | $13,691 |
| Morphine Sulfate ErMorphine Sulfate | 104 | $8,276 |
| Tegretol XrCarbamazepine | 15 | $6,973 |
| Fentanyl | 46 | $4,231 |
| Morphine Sulfate | 89 | $3,921 |
| Methadone Hcl | 98 | $3,725 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 75 | $3,502 |
| Oxycodone Hcl | 90 | $1,842 |
| Pregabalin | 65 | $1,455 |
| Carbamazepine ErCarbamazepine | 17 | $1,353 |
| Duloxetine Hcl | 43 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Synthroid | $111,590 | $66,04959 claims |
| PfizerNurtec Odt | $7,233 | $13,69112 claims |
| Upsher-smith Laboratories LLCTopiramate | $877 | $12621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in Orange
- Shalini ShahOrange$141K
- Eric ChangOrange$27K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.